Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker analytical and advisory services in translational and clinical research.
Following an assessment of ImmunoINSIGHT’s competence and capability, Synexa Life Sciences has selected Oncimmune’s ImmunoINSIGHTS platform to provide its clients access to specialist autoantibody services. This collaborative partnership will allow for comprehensive characterisation of the B-cell immune response in a wide range of disease and treatment indications.
Both companies utilise technologies to identify biological signatures, leveraging their deep expertise in the immunological underpinnings of health and disease to improve patient diagnostics and therapeutics. Over the next 18 months, Synexa Life Sciences plans to sign multiple new contracts with their partners for autoantibody profiling acting to broaden and enhance ImmunoINSIGHT’s own business development efforts.
This new strategic collaboration comes at a time when autoantibody profiling, which provides a depth and breadth of clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy, is experiencing substantial interest, with the market segment growing at approximately 27% year-upon-year.
Dr Adam M Hill, CEO of Oncimmune said: “We welcome this exciting initiative with Synexa Life Sciences, who have recognised the recent progress made by our ImmunoINSIGHTS platform. The ImmunoINSIGHTS team look forward to the opportunity to deliver high quality, value-adding analysis and interpretation of blood samples for Synexa and its clients, delivering a differentiated service to customers that are yet to engage with our proprietary technology platform.”
